We are analyzing https://link.springer.com/article/10.1186/ar3366.

Title:
Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study | Arthritis Research & Therapy
Description:
Introduction To assess the efficacy and safety of the interleukin-1 receptor (IL-1R) inhibitor anakinra in adult patients with refractory Still
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,625,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

patients, disease, anakinra, treatment, months, response, patient, stills, article, follow, clinical, complete, google, scholar, pubmed, median, laboratory, activity, table, cas, study, time, adult, levels, arthritis, data, therapy, mtx, efficacy, partial, drug, rheum, month, remission, reported, refractory, ilr, parameters, number, dose, systemic, information, treated, range, improvement, observed, onset, fever, monotherapy, ann,

Topics {✒️}

disease-modifying anti-rheumatic drugs article download pdf steroidal anti-inflammatory drugs il-1r inhibitor points elevated acute-phase proteins human il-1r antagonist articular involvement worsened articular involvement deteriorated prominent articular involvement elevated acute-phase reactants il-1r inhibitor anakinra anti-il1 drug anakinra demonstrated high il-1a il1-receptor antagonist anakinra drug-related adverse events anti-interleukin-1 treatment distinguishes il-1ra therapy due health assessment questionnaire effective steroid-sparing agent privacy choices/manage cookies il-1r inhibitor [15] meta-analysis article 08 steroid refractory adult-onset acute inflammatory response laboratory disease-related manifestations erythrocyte sedimentation rate visualized analogue scale hemophagocytic syndrome complicating acute-phase reactants authors’ original file steroid-sparing drugs persisting clinical activity prominent articular disease c-reactive protein partial clinical response clinical symptoms occurred visual analogue scale symptoms automatically resolved complete clinical response drug-related complications tumor necrosis factor tumour necrosis factor data included age persisting biological activity interleukin-1 receptor antagonist upper respiratory tract serial cytokine measurements treatment-resistant adult-onset high ferritin levels full access

Questions {❓}

Aarntzen EH, van Riel PL, Barrera P: Refractory adult onset Still's disease and hypersensitivity to non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors: are biological agents the solution?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study
         description:To assess the efficacy and safety of the interleukin-1 receptor (IL-1R) inhibitor anakinra in adult patients with refractory Still's disease. Twenty-five patients (13 males and 12 females, median age 32 years, median disease duration seven months) with Still's disease were treated with subcutaneous injections of anakinra (100 mg/day). Treatment was given as adjunct therapy in 16 patients and as standalone in 9 patients for a median time of 15 months (range 1.5-71). The clinical and laboratory parameters during follow-up were recorded. In 84% of patients the clinical activity resolved completely within a few days (median time 0.2 months), and response was maintained until the last visit in all but one patient. A complete response of all disease-related symptoms (clinical and laboratory) occurred subsequently within a median time of three months in 80% of patients. A partial clinical and laboratory improvement was shown in 12% and 16% of patients, respectively. The Visualized Analogue Scale and Health Assessment Questionnaire scores significantly decreased during treatment. The proportion of patients achieving the American College of Rheumatology 20 (ACR20) score (20% improvement) was 82% at one month and improved to 100% at one year. The mean oral corticosteroid dose was significantly reduced at each visit. Anakinra was discontinued due to unresponsiveness in one patient and due to relapsing disease in another. Treatment was also withdrawn in three patients with severe skin reactions (urticaria). Seven patients experienced an infection during follow-up. The rapid and sustained response in the majority of our patients encourages the use of anakinra in adults with Still's disease.
         datePublished:2011-06-17T00:00:00Z
         dateModified:2011-06-17T00:00:00Z
         pageStart:1
         pageEnd:9
         license:http://creativecommons.org/licenses/by/2.0/
         sameAs:https://doi.org/10.1186/ar3366
         keywords:
            Anakinra
            Complete Clinical Response
            TNFa Inhibitor
            Articular Involvement
            Partial Clinical Response
            Rheumatology
            Orthopedics
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Far3366/MediaObjects/13075_2011_Article_3124_Fig1_HTML.jpg
         isPartOf:
            name:Arthritis Research & Therapy
            issn:
               1478-6354
            volumeNumber:13
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Katerina Laskari
               affiliation:
                     name:National and Kapodistrian University of Athens
                     address:
                        name:Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Goudi, Greece
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Athanasios G Tzioufas
               affiliation:
                     name:National and Kapodistrian University of Athens
                     address:
                        name:Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Goudi, Greece
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Haralampos M Moutsopoulos
               affiliation:
                     name:National and Kapodistrian University of Athens
                     address:
                        name:Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Goudi, Greece
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study
      description:To assess the efficacy and safety of the interleukin-1 receptor (IL-1R) inhibitor anakinra in adult patients with refractory Still's disease. Twenty-five patients (13 males and 12 females, median age 32 years, median disease duration seven months) with Still's disease were treated with subcutaneous injections of anakinra (100 mg/day). Treatment was given as adjunct therapy in 16 patients and as standalone in 9 patients for a median time of 15 months (range 1.5-71). The clinical and laboratory parameters during follow-up were recorded. In 84% of patients the clinical activity resolved completely within a few days (median time 0.2 months), and response was maintained until the last visit in all but one patient. A complete response of all disease-related symptoms (clinical and laboratory) occurred subsequently within a median time of three months in 80% of patients. A partial clinical and laboratory improvement was shown in 12% and 16% of patients, respectively. The Visualized Analogue Scale and Health Assessment Questionnaire scores significantly decreased during treatment. The proportion of patients achieving the American College of Rheumatology 20 (ACR20) score (20% improvement) was 82% at one month and improved to 100% at one year. The mean oral corticosteroid dose was significantly reduced at each visit. Anakinra was discontinued due to unresponsiveness in one patient and due to relapsing disease in another. Treatment was also withdrawn in three patients with severe skin reactions (urticaria). Seven patients experienced an infection during follow-up. The rapid and sustained response in the majority of our patients encourages the use of anakinra in adults with Still's disease.
      datePublished:2011-06-17T00:00:00Z
      dateModified:2011-06-17T00:00:00Z
      pageStart:1
      pageEnd:9
      license:http://creativecommons.org/licenses/by/2.0/
      sameAs:https://doi.org/10.1186/ar3366
      keywords:
         Anakinra
         Complete Clinical Response
         TNFa Inhibitor
         Articular Involvement
         Partial Clinical Response
         Rheumatology
         Orthopedics
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Far3366/MediaObjects/13075_2011_Article_3124_Fig1_HTML.jpg
      isPartOf:
         name:Arthritis Research & Therapy
         issn:
            1478-6354
         volumeNumber:13
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Katerina Laskari
            affiliation:
                  name:National and Kapodistrian University of Athens
                  address:
                     name:Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Goudi, Greece
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Athanasios G Tzioufas
            affiliation:
                  name:National and Kapodistrian University of Athens
                  address:
                     name:Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Goudi, Greece
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Haralampos M Moutsopoulos
            affiliation:
                  name:National and Kapodistrian University of Athens
                  address:
                     name:Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Goudi, Greece
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Arthritis Research & Therapy
      issn:
         1478-6354
      volumeNumber:13
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:National and Kapodistrian University of Athens
      address:
         name:Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Goudi, Greece
         type:PostalAddress
      name:National and Kapodistrian University of Athens
      address:
         name:Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Goudi, Greece
         type:PostalAddress
      name:National and Kapodistrian University of Athens
      address:
         name:Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Goudi, Greece
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Katerina Laskari
      affiliation:
            name:National and Kapodistrian University of Athens
            address:
               name:Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Goudi, Greece
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Athanasios G Tzioufas
      affiliation:
            name:National and Kapodistrian University of Athens
            address:
               name:Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Goudi, Greece
               type:PostalAddress
            type:Organization
      name:Haralampos M Moutsopoulos
      affiliation:
            name:National and Kapodistrian University of Athens
            address:
               name:Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Goudi, Greece
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Goudi, Greece
      name:Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Goudi, Greece
      name:Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Goudi, Greece

External Links {🔗}(97)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.79s.

LINK . SPRINGER . COM {}